BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Wednesday, December 17, 2025
See today's BioWorld Asia
Home
» Providence and Everest’s vaccine is first mRNA in WHO’s Solidarity Trial Vaccines study
To read the full article
sign up for free
or
sign in
.
Providence and Everest’s vaccine is first mRNA in WHO’s Solidarity Trial Vaccines study
Dec. 21, 2021
By
David Ho
Everest Medicines Ltd. and Providence Therapeutics Holdings Inc.’s COVID-19 vaccine was cleared for inclusion in the World Health Organization’s (WHO) Solidarity Trial Vaccines clinical trial.
BioWorld Asia
Clinical
Coronavirus
Vaccine
Asia-Pacific
WHO